ClinicalTrials.gg
CompletedNCT04361136Updated Apr 28, 2026

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

A Phase 1 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Healthy, sponsored by LEO Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by LEO Pharma · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2020, 6 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This is a single-centre, randomised, vehicle-controlled, double-blind, within-subject comparison phase 1 clinical trial. The trial is designed to find out if delgocitinib cream can cause skin irritation after light exposure in people with healthy skin.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy subjects aged 18-64 years (inclusive).
  • Fitzpatrick skin type of I, II, or III.

Key Exclusion Criteria:

  • Atopic dermatitis, eczema, psoriasis, acne, dermatitis solaris or suntan that could interfere with the test field evaluation, hyperpigmentation, multiple naevi, tattoos, blemishes or dense body hair in the range of the test fields.
  • Any history of or presence of cancerous or precancerous skin lesions.
  • Any other skin disease or other visible skin condition noted on physical examination which in the investigator's opinion might interfere with the evaluation of the test field reaction.
  • Known disease that can be induced by ultraviolet (UV) light.
  • Use of any topical or systemic medication which could interfere with the trial objective within 2 weeks before randomisation until end of trial.
  • Use of drugs which might cause photobiologic or phototoxic reactions within 4 weeks before randomisation until end of trial.
  • Foreseeable intensive UV light exposure (solar or artificial) to test fields within 4 weeks before randomisation until end of trial.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream 1 mg/g

    Single topical occlusive administration

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 3 mg/g

    Single topical occlusive administration

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 8 mg/g

    Single topical occlusive administration

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 20 mg/g

    Single topical occlusive administration

    Drug: Delgocitinib cream

  • Placebo comparator
    Delgocitinib cream vehicle

    Single topical occlusive administration

    Drug: Delgocitinib cream vehicle

Interventions

  • Cream for topical application

    Also known as: LEO 124249 cream

  • DrugDelgocitinib cream vehicle

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

    Also known as: LEO 124249 cream vehicle

06

What researchers measure

Primary outcomes

  1. Positive skin reaction at 24 hours or 48 hours after irradiation

    A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field. The grading for the skin reaction score will be performed according to the following 5-point scale: * 0 No reaction * 1 Erythema * 2 Erythema with dermal infiltrate * 3 Erythema with papulovesicles * 4 Erythema with blisters, erosions

    Time frame: Up to 48 hours after irradiation

Secondary outcomes

  1. Positive skin reaction at 24 hours after irradiation

    A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field. The grading for the skin reaction score will be performed according to the following 5-point scale: * 0 No reaction * 1 Erythema * 2 Erythema with dermal infiltrate * 3 Erythema with papulovesicles * 4 Erythema with blisters, erosions

    Time frame: 24 hours after irradiation

  2. Positive skin reaction at 48 hours after irradiation

    A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field. The grading for the skin reaction score will be performed according to the following 5-point scale: * 0 No reaction * 1 Erythema * 2 Erythema with dermal infiltrate * 3 Erythema with papulovesicles * 4 Erythema with blisters, erosions

    Time frame: 48 hours after irradiation

Other outcomes

  1. Number of treatment-emergent adverse events from baseline to Day 4

    Time frame: From time of first investigational medicinal product application (Day 1) until Day 4

07

Study locations

1 site
  • Bioskin Research Center Dermatology
    Hamburg, 20095, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in May 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2020
First posted
Apr 24, 2020
StartActual
Apr 23, 2020
Primary completionActual
May 30, 2020
CompletionActual
May 30, 2020
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04361136
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
Apr 23, 2020
Primary completion
May 30, 2020
Completion
May 30, 2020
Last update
Apr 28, 2026

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion